Please ensure Javascript is enabled for purposes of website accessibility

3 Top Stocks for Investing in Silicon Valley

By Tim Beyers - May 28, 2015 at 5:00PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The fastest growers don't always get the headlines.

A skyline view of the innovation hub we know as Silicon Valley. Credit: Wikimedia Commons. 

Silicon Valley has been part of the tech lore for well over a half-century. From Gordon Moore and the rest of the "traitorous eight" that formed Fairchild Semiconductor, to Steve Jobs and Steve Wozniak founding Apple in a garage, to Mark Zuckerberg leaving Harvard to grow Facebook, the Valley is home to some of the most remarkable stories in the history of business.

And it's still a major commerce center. Each year, Silicon Valley's various companies produce hundreds of billions of dollars in revenue and tens of billions in profits. Apple and Facebook alone accounted for $212.3 billion in revenue and $47.4 billion in profit. 

A good portion of that is then funneled back into the community in the form of research and development and venture capital. The quarterly MoneyTree report from PricewaterhouseCoopers put first-quarter 2015 VC investment in Silicon Valley at just over $6 billion, or 45% of the U.S. total. In Silicon Valley, chasing the next big thing is a way of life.

The best of the best
How do you single out the cream of such a rich crop? Easy: you take subjectivity out of the equation. The following three Silicon Valley businesses had the highest revenue growth last year. 

  1. Depomed (ASRT -2.80%). A sort-of junk dealer for the biotech industry in that the company acquires rights to approved treatments that go largely unused, and then markets the heck out of them. In 2014, that strategy pushed revenue up 191%. More recently, the company acquired narcotic pain reliever Nucynta for $1.05 billion. With the company's first-quarter product sales soaring 47% without the new drug's help, it's looking like 2015 will be just as good -- or even better -- than 2014.
  2. Pharmacyclics. Founded in 1991, the old biotech found new life in 2014 as revenue soared 180% year over year thanks to the popularity of its signature cancer treatment, Imbruvica. That attracted a suitor: AbbVie (ABBV 0.40%), which earlier this month completed its $21 billion purchase of the drugmaker.
  3. FireEye (MNDT -0.04%). The cybersecurity supplier that specializes in "vector-specific" defense grew revenue 163% last year as dozens of companies suffered high-profile data breaches. Appliances for handling Web, email, files, and mobile devices, among other things, appear well positioned as corporate America prepares boosts its spending on network defense. Gartner expects total information security spending to grow 8.2% this year, to $76.9 billion.

Death and disease: the ultimate growth catalysts
If there's a pattern here it's that many of Silicon Valley's top performers operate outside the information technology industry. Four of last year's fastest growers specialize in some form of biotech. Surprised? I wouldn't be. The Valley has always been home to pioneering biotech researchers, including no-longer-independent Genentech.

Maybe that's as it should be. For all its peculiarities, the human body has survived hundreds of thousands of years of evolution. You might even call it the ultimate technology. Silicon Valley's would-be biotech barons are finding ways to tune it.

Tim Beyers worked in Silicon Valley in the days before HBO decided to make a show about it. He's also a member of the Motley Fool Rule Breakers stock-picking team and the Motley Fool Supernova Odyssey I mission and owned shares of Apple at the time of publication. Check out Tim's web home and portfolio holdings or connect with him on Google+Tumblr, or Twitter, where he goes by @milehighfool.

The Motley Fool recommends Apple, Facebook, FireEye, and Gartner. The Motley Fool owns shares of Apple and Facebook. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Depomed, Inc. Stock Quote
Depomed, Inc.
$3.47 (-2.80%) $0.10
AbbVie Inc. Stock Quote
AbbVie Inc.
$141.85 (0.40%) $0.56
Mandiant, Inc. Stock Quote
Mandiant, Inc.
$22.88 (-0.04%) $0.01

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 08/19/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.